Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atrasentan + Doxil in Recurrent Ovarian Cancer
NCT00653328Phase 2Terminated
- Sponsor
- Vanderbilt-Ingram Cancer Center
- Start
- May 2003
- Primary completion
- Mar 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of atrasentan in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by Vanderbilt-Ingram Cancer Center. Primary endpoint: Median Time to Tumor Progression. Started May 2003; status: terminated.
02
Drugs
atrasentan
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT00653328.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00653328.